SCHEMBL6679405

SCHEMBL6679405

Cc1cc(Oc2c(C)cc([N+](=O)[O-])cc2Cl)ccc1OCOCC[Si](C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
S1PR4 O95977 3/20 0.36
MAPT P10636 5/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 3/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 2/20 0.36
PDE7A Q13946 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TBXA2R P21731 1/20 0.35
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6658711 0.90 MAPT (0.39) KMT2AMEN1S1PR4MAPTLMNA
SCHEMBL6663199 0.87 S1PR4 (0.35) KMT2AMEN1S1PR4MAPTLMNA
SCHEMBL15508768 0.82 ALDH1A1 (0.44) KMT2AMEN1S1PR4MAPTLMNA
SCHEMBL15508874 0.79 RAB9A (0.55) KMT2AMEN1S1PR4MAPTLMNA
SCHEMBL27247652 0.74 RAB9A (0.44) KMT2AMEN1MAPTLMNAHPGD
SCHEMBL18998671 0.74 MEN1 (0.51) KMT2AMEN1MAPTLMNAHPGD
SCHEMBL29612490 0.72 MAPT (0.35) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL28730654 0.72 MAPT (0.35) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL30442588 0.72 LMNA (0.48) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL7042843 0.71 HTT (0.50) KMT2AMEN1MAPTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157001-B1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS PFIZER PROD INC (US) 2004-08-04 EP disclosed
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2003-06-19 US disclosed
US-6545018-B2 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis PFIZER INC. 2003-04-08 US disclosed
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2002-04-25 US disclosed
US-6326398-B1 Oxamic acids and derivatives as thyroid receptor ligands PFIZER INC. 2001-12-04 US disclosed
EP-1157001-A1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2001-11-28 EP disclosed
WO-2000051971-A1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, TSHR KMT2A 4235/4885MEN1 2031/4885S1PR4 579/4885
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, OXGR1 KMT2A 3930/4885MEN1 2554/4885S1PR4 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.